55 participants
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-07-07
- Start Date:
- 2021-02-04
- Completion:
- 2023-05-22
Conditions
- Severe Hemophilia A
Interventions
- DRUG